Research progress on whether sotoracib (AMG 510) can treat KRAS mutant cholangiocarcinoma

Sotorasib (trade name Lumakras) is a targeted therapy drug targeting the KRAS G12C mutation and has been approved in solid tumors such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). However, research into its use in cholangiocarcinoma (cholangiocarcinoma) is still in its preliminary stages, and there is not yet enough clinical data to prove its efficacy.

The incidence of KRAS mutations in cholangiocarcinoma is relatively low, about15.6%, and common mutation types include Including G12D, G12V and Q61H etc. Among them, the proportion of G12C mutations in cholangiocarcinoma is even lower. Therefore, the application of sotoracib as a specific inhibitor of KRAS G12C mutation in cholangiocarcinoma is limited.

Currently, there are no clinical trial data on the use of sotoraxib in patients with cholangiocarcinoma. Most of the research on sotorasib has focused on tumor types such as NSCLC and CRC. For example, in clinical trials such as CodeBreaK 100 and CodeBreaK 300, sotoraxib was found to be effective in KRAS It has shown certain efficacy in patients with G12C mutated NSCLC and CRC. However, these findings have not yet been validated in patients with cholangiocarcinoma.

Nonetheless, with in-depth research on the molecular characteristics of cholangiocarcinoma, more targeted treatment strategies for KRAS mutant cholangiocarcinoma may be proposed in the future. At present, the treatment for cholangiocarcinoma is still based on comprehensive methods such as surgery, radiotherapy, chemotherapy and targeted therapy. For patients with cholangiocarcinoma with KRAS mutations, they still need to choose the most appropriate treatment plan under the guidance of professional doctors.

In conclusion, although sotorasiib has shown some efficacy in other tumor types, its efficacy in KRAS G12CThe application in mutant cholangiocarcinoma still needs more clinical research data to support. Patients should fully communicate with their doctors to understand the latest research progress and formulate individualized treatment plans.

Reference materials:https://www.drugs.com/